Palvella wins FDA Priority Review for QTORIN rapamycin NDA
Palvella Therapeutics has announced that the US Food and Drug Administration has accepted its New Drug Application for QTORIN 3.9% rapamycin anhydrous gel and granted Priority Review status. The FDA has set a PDUFA target action date of 28 February 2027, putting the Wayne, Pennsylvania company on a potential path to commercialisation in the first half of next year.
If approved, QTORIN rapamycin would be the first FDA-sanctioned treatment for microcystic lymphatic malformations, a rare, progressive genetic condition estimated to affect more than 30,000 diagnosed individuals in the United States. The disease arises from dysregulation of the PI3K/mTOR signalling pathway, causing malformed lymphatic vessels that can protrude through the skin, leak persistently, and drive recurrent infections and hospitalisation. Existing interventions, including surgery, sclerotherapy and laser treatment, are limited by high recurrence rates, while systemic PI3K/mTOR inhibitors carry chronic safety concerns, particularly in children.
Phase 3 results and regulatory backing
The NDA is underpinned by results from the Phase 3 SELVA study, which Palvella says achieved statistical significance across all six prespecified efficacy endpoints, each with a p-value below 0.001. On the primary endpoint, the mLM-IGA scale, 95% of participants aged six years and older who completed the efficacy evaluation period demonstrated measurable improvement. The company reported that QTORIN rapamycin was well tolerated in SELVA, with no drug-related serious adverse events and systemic rapamycin concentrations below 2 ng/mL across all participants and timepoints, a finding the company regards as meaningful given longstanding concerns about systemic exposure with oral mTOR inhibitors in paediatric populations.
The product has already received Breakthrough Therapy, Fast Track and Orphan Drug designations from the FDA, and the development programme has attracted grant funding from the agency's Office of Orphan Products Development. The Phase 2 data that earned Breakthrough Therapy designation is also included in the NDA filing.
"We believe we are closer than ever to delivering on that mission," said Wes Kaupinen, founder and chief executive of Palvella, referring to the company's stated goal of bringing first-in-disease therapies to patients who currently lack approved options.
Commercial readiness and pipeline
Palvella says it is preparing for a standalone commercial launch and has assembled field-based medical science liaisons across the United States, a patient services organisation, and rare disease commercial leadership. Launch preparations already under way include disease education, specialist engagement, patient identification, and market access planning.
Beyond microcystic LMs, the company is developing QTORIN rapamycin for cutaneous venous malformations and clinically significant angiokeratomas, as well as a separate candidate, QTORIN pitavastatin, for disseminated superficial actinic porokeratosis.
The rare skin disease and vascular anomaly space is a niche but increasingly active area for biotech investment, driven in part by the FDA's Orphan Drug and Breakthrough Therapy designation pathways, which reduce the cost and timeline burden for small developers. Palvella's QTORIN platform, which reformulates known pharmacological agents into a targeted anhydrous gel delivery system, fits a broader industry trend of repurposing well-characterised molecules in new formulations or indications to de-risk clinical development. Several other companies are pursuing mTOR-pathway modulation for vascular anomalies, though Palvella appears to be the furthest advanced in the topical gel format for this specific indication. Approval would immediately transition the company from clinical-stage to commercial-stage, a significant operational shift that will test its newly built commercial infrastructure against a rare-disease patient population that requires specialist identification and support.